Physician profile
Patrick Parisi
NPI 1649286170
$4,103.10
in general payments reported to CMS, 2019-2025
26 companies · $928 in 2025
The $928 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $786 · 2020: $116 · 2021: $140 · 2022: $412 · 2023: $471 · 2024: $1,250 · 2025: $928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,459 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,458.98 |
| Education | $189.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $537.15 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $526.34 | 2021-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals Lp | $407.10 | 2019-2024 | Farxiga |
| Actelion Pharmaceuticals US, INC. | $331.87 | 2024-2025 | Opsumit, Uptravi |
| Pfizer INC. | $300.15 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $250.96 | 2019-2023 | Xarelto |
| Boston Scientific Corporation | $233.00 | 2019-2023 | Watchman Flx, Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.39 | 2019-2025 | Jardiance |
| Medtronic Vascular, INC. | $174.09 | 2019 | |
| Abbott Laboratories | $169.33 | 2019-2023 | Mitraclip |
| Lilly USA, LLC | $146.65 | 2025 | Zepbound |
| Scpharmaceuticals INC. | $128.90 | 2023-2025 | |
| Medtronic, INC. | $105.01 | 2024 | Corevalve Evolut R |
| Merck Sharp & Dohme LLC | $93.42 | 2022-2025 | Verquvo, Capvaxive |
| Amgen INC. | $84.88 | 2020-2025 | Repatha, Repatha |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $78.83 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $70.93 | 2023-2024 | Inpefa |
| Edwards Lifesciences Corporation | $56.51 | 2019 | |
| Alnylam Pharmaceuticals INC. | $35.66 | 2025 | Onpattro |
| Regeneron Healthcare Solutions, INC. | $29.05 | 2019-2023 | Evkeeza |
| Atricure, INC. | $26.92 | 2025 | Epi-Ease Epicardial Access System |
| Bridgebio Pharma, INC. | $21.76 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $18.69 | 2024 | |
| Bardy Diagnostics, INC. | $16.19 | 2022 | |
| Esperion Therapeutics, INC. | $14.20 | 2025 | Nexletol |
| Gilead Sciences, INC. | $13.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Parisi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.